Metabolic and endocrine studies in women using norethindrone acetate implant

Subcutaneously administered implant-D containing 40 mg of Norethindrone acetate in a single silastic implant was offered to 79 subjects who desired spacing of their family. The effect of constant release of steroid from this device on metabolic and endocrine functions was studied. Each subject in th...

Full description

Saved in:
Bibliographic Details
Published inContraception (Stoneham) Vol. 19; no. 2; pp. 135 - 144
Main Authors Shahani, S.M., Kulkarni, P.P., Bhate, P.A., Patel, K.L.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.02.1979
Subjects
Adult
Blood Chemical Analysis
Contraceptive Agents, Female - pharmacology
Drug Implants
Female
Humans
Liver - metabolism
Metabolism - drug effects
Norethindrone - pharmacology
Online AccessGet full text

Cover

More Information
Summary:Subcutaneously administered implant-D containing 40 mg of Norethindrone acetate in a single silastic implant was offered to 79 subjects who desired spacing of their family. The effect of constant release of steroid from this device on metabolic and endocrine functions was studied. Each subject in the pretreatment state served as her own control. The device was removed at 8 months initially and subsequently at 5–6 months. The clinical acceptability of this method was fairly high. The results reported in this study show that Norethindrone acetate administered in this way did not cause any adverse reactions on endocrine and metabolic functions as gauged by the parameters analysed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0010-7824
1879-0518
DOI:10.1016/S0010-7824(79)80026-8